Ionis Pharmaceuticals Wins EU Regulatory Support for Tryngolza

The recommendation positions Tryngolza as an adjunct to diet, functioning alongside existing lipid-lowering therapies to manage patients with dangerously high triglyceride levels. These patients face a heightened risk of acute pancreatitis and other severe health complications, making the intervention a critical component of their clinical care. The European Commission typically aligns with the committee’s guidance and is expected to deliver a final ruling by the end of the year. This progress follows the drug's initial approval by the U.S. Food and Drug Administration, which cleared the treatment for use in June.